



Clinical trial results:

A double-blind, randomized, placebo-controlled, Phase I/II Study evaluating the safety, immunogenicity and clinical activity of neoadjuvant treatment with WT1-A10 + AS15 Antigen-Specific Cancer Immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II or III breast cancer.

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2010-019909-42 |
| Trial protocol | BE DE GB DK |
| Global end of trial date | 14 November 2014 |

Results information

| | |
|--------------------------------|---|
| Result version number | v2 (current) |
| This version publication date | 20 June 2021 |
| First version publication date | 05 March 2016 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Results have been amended to account for consistency with other registries. |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 113172 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01220128 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 04 May 2015 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 14 November 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 14 November 2014 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The study was conducted in 2 consecutive segments with specific objectives:

Phase I Segment

-Objectives concerning cohorts A, B, C and D: To evaluate the safety and immunogenicity of WT1 ASCI administration in combination with standard treatment.

Phase II Segment

-To further assess the safety, immunogenicity and the clinical activity of WT1 ASCI in combination with standard treatment per group and in the overall population (i.e., including the patients enrolled during the Phase I segment of the study).

Protection of trial subjects:

The vaccine/placebo recipients were to be observed closely for at least 30 minutes with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccine(s)/product(s).

For patients in Cohort B and C, the study product administration had to be done at least 60 minutes prior to administration of chemotherapy. The patient was observed closely for at least 30 minutes following the administration of the study product with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 11 April 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | United Kingdom: 3 |
| Country: Number of subjects enrolled | Belgium: 9 |
| Country: Number of subjects enrolled | France: 5 |
| Country: Number of subjects enrolled | Germany: 35 |
| Country: Number of subjects enrolled | Italy: 3 |
| Country: Number of subjects enrolled | Russian Federation: 5 |
| Country: Number of subjects enrolled | United States: 6 |
| Worldwide total number of subjects | 66 |
| EEA total number of subjects | 55 |

Notes:

| Subjects enrolled per age group | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 40 |
| From 65 to 84 years | 26 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Out of the 66 enrolled patients, 6 patients did not receive study product doses and were hence excluded prior to study start.

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

| | |
|------------------------------|---------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Assessor |

Blinding implementation details:

Double-blind, randomized, placebo-controlled study including 2 segments, a Phase I segment and a Phase II segment. The Phase I segment was a randomized (2:1), double-blinded, placebo-controlled study for cohorts A, B and C and an open label, single treatment schedule study for Cohort D. The Phase II segment was a randomized (2:1), double-blinded, placebo-controlled study for cohorts A, B, C, and E.

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Cohort A-WT1 Group |

Arm description:

This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of WT1 ASCI according to the treatment schedule.

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | WT1-A10 + AS15 |
| Investigational medicinal product code | WT1-A10 + AS15 |
| Other name | WT1 ASCI - GSK2302024A |
| Pharmaceutical forms | Powder for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 6 or 8 injections at 3 weeks apart of WT1 ASCI, injected intramuscularly in the deltoid or lateral region of the thigh.

| | |
|--|---------------------|
| Investigational medicinal product name | Aromatase inhibitor |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).

| | |
|------------------|------------------------|
| Arm title | Cohort A-Placebo Group |
|------------------|------------------------|

Arm description:

This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.

| | |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

| | |
|--|--|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | Placebo |
| Other name | |
| Pharmaceutical forms | Concentrate and solvent for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 6 or 8 doses at 3 weeks apart of placebo (sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion), injected intramuscularly in the deltoid or lateral region of the thigh.

| | |
|--|---------------------|
| Investigational medicinal product name | Aromatase inhibitor |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).

| | |
|------------------|--------------------|
| Arm title | Cohort B-WT1 Group |
|------------------|--------------------|

Arm description:

This group included breast cancer patients who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel, according to the treatment schedule.

| | |
|--|-------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | WT1-A10 + AS15 |
| Investigational medicinal product code | WT1-A10 + AS15 |
| Other name | WT1 ASCI |
| Pharmaceutical forms | Powder for suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 6 or 8 injections at 3 weeks apart of WT1 ASCI, injected intramuscularly in the deltoid or lateral region of the thigh.

| | |
|--|-----------------|
| Investigational medicinal product name | 5-Fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohort B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Epirubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Groups, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: only in the 8 WT1 ASCI/Placebo-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|------------------|------------------------|
| Arm title | Cohort B-Placebo Group |
|------------------|------------------------|

Arm description:

This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|--|--|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | Placebo |
| Other name | |
| Pharmaceutical forms | Concentrate and solvent for solution for injection |
| Routes of administration | Intraventricular use |

Dosage and administration details:

Subjects received 6 or 8 doses at 3 weeks apart of Placebo (sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion), injected intramuscularly in the deltoid or lateral region of

the thigh.

| | |
|--|-----------------|
| Investigational medicinal product name | 5-Fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohort B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Epirubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Groups, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: only in the 8 WT1 ASCI/Placebo-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|------------------|--------------------|
| Arm title | Cohort C-WT1 Group |
|------------------|--------------------|

Arm description:

This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1-ASCI, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | WT1-A10 + AS15 |
| Investigational medicinal product code | WT1-A10 + AS15 |
| Other name | WT1 ASCI |
| Pharmaceutical forms | Powder for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 6 or 8 injections at 3 weeks apart of WT1-ASCI, injected intramuscularly in the deltoid or lateral region of the thigh .

| | |
|--|-----------------|
| Investigational medicinal product name | Trastuzumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. The administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle).

| | |
|--|-----------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).

| | |
|--|-----------------|
| Investigational medicinal product name | 5-Fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohort B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Epirubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Groups, the administration was on Day 14 of each cycle.

| | |
|--|-----------------|
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: only in the 8 WT1 ASCI/Placebo-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|------------------|------------------------|
| Arm title | Cohort C-Placebo Group |
|------------------|------------------------|

Arm description:

This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing

breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|--|--|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | Placebo |
| Other name | |
| Pharmaceutical forms | Concentrate and solvent for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 6 or 8 doses at 3 weeks apart of Placebo (sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion), injected intramuscularly in the deltoid or lateral region of the thigh.

| | |
|--|-----------------|
| Investigational medicinal product name | Carboplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).

| | |
|--|-----------------|
| Investigational medicinal product name | Trastuzumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. The administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle).

| | |
|--|-----------------|
| Investigational medicinal product name | 5-Fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|------------------|
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohort B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| | |
|--|-----------|
| Investigational medicinal product name | Docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |

| | |
|---|-----------------------------------|
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Epirubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Groups, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: only in the 8 WT1 ASCI/Placebo-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Arm title | Cohort D-WT1-D14 Group |
| Arm description: | |
| This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Arm type | Experimental |
| Investigational medicinal product name | WT1-A10 + AS15 |
| Investigational medicinal product code | WT1-A10 + AS15 |
| Other name | WT1 ASCI |
| Pharmaceutical forms | Powder for solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| Subjects received 6 or 8 injections at 3 weeks apart, of WT1 ASCI injected intramuscularly in the deltoid or lateral region of the thigh . | |
| Investigational medicinal product name | 5-Fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |

| | |
|---|------------------|
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Cyclophosphamide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohort B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Docetaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/placebo-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Doxorubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Epirubicin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| Administered intravenously in Cohort B, C and D Groups: for the 6 WT1 ASCI/Placebo-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI/Placebo-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Groups, the administration was on Day 14 of each cycle. | |
| Investigational medicinal product name | Paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Administered intravenously in Cohort B, C and D Groups: only in the 8 WT1 ASCI/Placebo-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D Group, the administration was on Day 14 of each cycle.

| Number of subjects in period 1^[1] | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group |
|---|--------------------|------------------------|--------------------|
| Started | 15 | 7 | 9 |
| Completed | 11 | 6 | 6 |
| Not completed | 4 | 1 | 3 |
| Adverse event, serious fatal | 2 | - | - |
| Consent withdrawn by subject | 1 | - | - |
| Sponsor study termination | - | 1 | - |
| Adverse event, non-fatal | 1 | - | - |
| Unspecified | - | - | 1 |
| Progressive disease | - | - | 2 |

| Number of subjects in period 1^[1] | Cohort B-Placebo Group | Cohort C-WT1 Group | Cohort C-Placebo Group |
|---|------------------------|--------------------|------------------------|
| Started | 6 | 11 | 4 |
| Completed | 6 | 11 | 4 |
| Not completed | 0 | 0 | 0 |
| Adverse event, serious fatal | - | - | - |
| Consent withdrawn by subject | - | - | - |
| Sponsor study termination | - | - | - |
| Adverse event, non-fatal | - | - | - |
| Unspecified | - | - | - |
| Progressive disease | - | - | - |

| Number of subjects in period 1^[1] | Cohort D-WT1-D14 Group |
|---|------------------------|
| Started | 8 |
| Completed | 3 |
| Not completed | 5 |
| Adverse event, serious fatal | 1 |
| Consent withdrawn by subject | - |
| Sponsor study termination | 1 |
| Adverse event, non-fatal | 3 |
| Unspecified | - |

| | |
|---------------------|---|
| Progressive disease | - |
|---------------------|---|

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of the 66 enrolled patients, 6 patients did not receive study product doses and were hence excluded prior to study start.

Baseline characteristics

Reporting groups

| | |
|---|------------------------|
| Reporting group title | Cohort A-WT1 Group |
| Reporting group description: This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of WT1 ASCI according to the treatment schedule. | |
| Reporting group title | Cohort A-Placebo Group |
| Reporting group description: This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule. | |
| Reporting group title | Cohort B-WT1 Group |
| Reporting group description: This group included breast cancer patients who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel, according to the treatment schedule. | |
| Reporting group title | Cohort B-Placebo Group |
| Reporting group description: This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort C-WT1 Group |
| Reporting group description: This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1-ASCI, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort C-Placebo Group |
| Reporting group description: This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort D-WT1-D14 Group |
| Reporting group description: This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |

| Reporting group values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group |
|---|--------------------|------------------------|--------------------|
| Number of subjects | 15 | 7 | 9 |
| Age categorical Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |

| | | | |
|-------------------|--|--|--|
| 85 years and over | | | |
|-------------------|--|--|--|

| | | | |
|---|----------------|---------------|----------------|
| Age continuous Units: years arithmetic mean standard deviation | 69.3 ± 10.4 | 70.9 ± 7.1 | 49.3 ± 15.6 |
| Gender categorical Units: Subjects | | | |
| Female | 15 | 7 | 9 |
| Male | 0 | 0 | 0 |

| Reporting group values | Cohort B-Placebo Group | Cohort C-WT1 Group | Cohort C-Placebo Group |
|---|------------------------|--------------------|------------------------|
| Number of subjects | 6 | 11 | 4 |
| Age categorical Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age continuous Units: years arithmetic mean standard deviation | 60.7 ± 9.8 | 52.9 ± 10.6 | 53.3 ± 6.2 |
| Gender categorical Units: Subjects | | | |
| Female | 6 | 11 | 4 |
| Male | 0 | 0 | 0 |

| Reporting group values | Cohort D-WT1-D14 Group | Total | |
|--|------------------------|-------|--|
| Number of subjects | 8 | 60 | |
| Age categorical Units: Subjects | | | |
| In utero | | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | | 0 | |
| Newborns (0-27 days) | | 0 | |
| Infants and toddlers (28 days-23 months) | | 0 | |
| Children (2-11 years) | | 0 | |
| Adolescents (12-17 years) | | 0 | |
| Adults (18-64 years) | | 0 | |
| From 65-84 years | | 0 | |
| 85 years and over | | 0 | |

| | | | |
|--------------------|-------|----|--|
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 49.6 | | |
| standard deviation | ± 8.7 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 8 | 60 | |
| Male | 0 | 0 | |

End points

End points reporting groups

| | |
|---|------------------------|
| Reporting group title | Cohort A-WT1 Group |
| Reporting group description: This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of WT1 ASCI according to the treatment schedule. | |
| Reporting group title | Cohort A-Placebo Group |
| Reporting group description: This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule. | |
| Reporting group title | Cohort B-WT1 Group |
| Reporting group description: This group included breast cancer patients who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel, according to the treatment schedule. | |
| Reporting group title | Cohort B-Placebo Group |
| Reporting group description: This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort C-WT1 Group |
| Reporting group description: This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1-ASCI, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort C-Placebo Group |
| Reporting group description: This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |
| Reporting group title | Cohort D-WT1-D14 Group |
| Reporting group description: This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. | |

Primary: Number of subjects with severe toxicities

| | |
|---|--|
| End point title | Number of subjects with severe toxicities ^[1] |
| End point description: Severe toxicity was defined as follows: – A Grade 3 or higher toxicity that is related or possibly related to the combined administration of standard treatment and GSK2302024A/placebo – A decrease in Left Ventricular Ejection Fraction (LVEF) from baseline with ≥ 10 points and at $< 50\%$ that is related or possibly related to the combined administration of treatment and that is confirmed by a second LVEF assessment within approximately 3 weeks. – A Grade 2 or higher cardiac ischemia/infarction that is related or possibly related to the combined administration of standard treatment and GSK2302024A /placebo. – A Grade 2 or higher allergic reaction occurring within 24 hours following the administration. – A Grade 3 or higher blood/bone marrow toxicity that was considered as related or possibly related to the combined Administration. – A decrease in renal function at the time of administration that was considered as related or possibly related. | |
| End point type | Primary |
| End point timeframe: From Week 0 to Week 26/32 (period starting from WT1 ASCI/placebo treatment allocation and ending | |

with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any severe toxicity | 0 | 0 | 1 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any severe toxicity | 1 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of patients with an anti-WT1 humoral response

| | |
|-----------------|---|
| End point title | Number of patients with an anti-WT1 humoral response ^[2] |
|-----------------|---|

End point description:

For initially seronegative patients: post-administration antibody concentration ≥ 9 EU/mL

For initially seropositive patients: post-administration antibody concentration ≥ 2 fold the pre-administration antibody concentration.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At post-WT1 ASCI/placebo Dose 4 (Week 13)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 10 | 4 | 8 | 6 |
| Units: Subjects | | | | |
| Anti-WT1 response | 10 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 3 | 3 | |
| Units: Subjects | | | | |
| Anti-WT1 response | 6 | 0 | 2 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of patients with adverse events (AEs)

| | |
|-----------------|---|
| End point title | Number of patients with adverse events (AEs) ^[3] |
|-----------------|---|

End point description:

An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any AE(s) | 15 | 5 | 9 | 6 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any AE(s) | 11 | 4 | 7 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with serious adverse events SAE(s)

| | |
|-----------------|--|
| End point title | Number of subjects with serious adverse events SAE(s) ^[4] |
|-----------------|--|

End point description:

A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, causes disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient.

In this study, an event which was part of the natural course of the disease under study (i.e., disease progression/recurrence) was captured in the study/as an efficacy measure. Therefore it was not reported as an SAE. Progression/recurrence of the tumor was recorded in the clinical assessments in the electronic case report form (eCRF). Death due to progressive disease was recorded on a specific form in the eCRF but not as an SAE.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From Week 0 to Week 26/32 (period starting from WT1 ASCI/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any SAE(s) | 3 | 0 | 4 | 2 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any SAE(s) | 5 | 1 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with alanine aminotransferase increased abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with alanine aminotransferase increased abnormality, by CTCAE maximum grade ^[5] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5)

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 12 | 5 | 8 | 4 |
| Grade 1 | 2 | 1 | 1 | 2 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 1 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 6 | 2 | 1 | |
| Grade 1 | 5 | 2 | 2 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with alkaline phosphatase increased abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with alkaline phosphatase increased abnormality, by CTCAE maximum grade ^[6] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 10 | 5 | 8 | 6 |
| Grade 1 | 5 | 1 | 1 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 7 | 3 | 1 | |
| Grade 1 | 4 | 1 | 2 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with anemia, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with anemia, by CTCAE maximum grade ^[7] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 12 | 7 | 1 | 0 |
| Grade 1 | 2 | 0 | 7 | 4 |
| Grade 2 | 1 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 1 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 0 | 0 | 2 | |
| Grade 1 | 7 | 3 | 2 | |
| Grade 2 | 4 | 1 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with aspartate aminotransferase increased abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with aspartate aminotransferase increased abnormality, by CTCAE maximum grade ^[8] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 12 | 4 | 8 | 6 |
| Grade 1 | 3 | 2 | 1 | 0 |
| Grade 2 | 1 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 7 | 1 | 2 | |
| Grade 1 | 4 | 3 | 1 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with blood bilirubin increased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with blood bilirubin increased abnormality, by CTCAE maximum grade ^[9] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 5 | 9 | 6 |
| Grade 1 | 0 | 1 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 11 | 2 | 3 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 0 | 1 | 0 | |
| Grade 3 | 0 | 1 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with creatine increased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with creatine increased abnormality, by CTCAE maximum grade ^[10] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 11 | 4 | 8 | 5 |
| Grade 1 | 4 | 2 | 1 | 1 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 4 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 3 | 3 | |
| Grade 1 | 1 | 1 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hemoglobin increased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with hemoglobin increased abnormality, by CTCAE maximum grade ^[11] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 6 | 9 | 6 |
| Grade 1 | 0 | 1 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 11 | 4 | 4 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hypercalcemia abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with hypercalcemia abnormality, by CTCAE maximum grade ^[12] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 14 | 3 | 8 | 6 |
| Grade 1 | 1 | 3 | 1 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 3 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 11 | 4 | 3 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hyperkalemia abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with hyperkalemia abnormality, by CTCAE maximum grade ^[13] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 5 | 7 | 6 |
| Grade 1 | 0 | 1 | 1 | 0 |
| Grade 2 | 0 | 0 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 4 | 3 | |
| Grade 1 | 1 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hypernatremia abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with hypernatremia abnormality, by CTCAE maximum grade ^[14] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 14 | 4 | 9 | 6 |
| Grade 1 | 1 | 2 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 4 | 3 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 1 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hypoalbuminemia abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with hypoalbuminemia abnormality, by CTCAE maximum grade ^[15] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 13 | 6 | 9 | 5 |
| Grade 1 | 1 | 0 | 0 | 1 |
| Grade 2 | 1 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 9 | 3 | 3 | |
| Grade 1 | 2 | 1 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hypocalcemia abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with hypocalcemia abnormality, by CTCAE maximum grade ^[16] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 12 | 6 | 5 | 4 |
| Grade 1 | 3 | 0 | 3 | 1 |
| Grade 2 | 0 | 0 | 1 | 1 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 3 | 3 | |
| Grade 1 | 1 | 1 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hypokalemia abnormality, by CTCAE maximum grade

| | |
|-----------------|---|
| End point title | Number of subjects with hypokalemia abnormality, by CTCAE maximum grade ^[17] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 6 | 9 | 6 |
| Grade 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 4 | 3 | |
| Grade 1 | 1 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with hyponatremia abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with hyponatremia abnormality, by CTCAE maximum grade ^[18] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and post 30 days post last administration

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 6 | 5 | 6 |
| Grade 1 | 0 | 0 | 4 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 11 | 4 | 3 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with lymphocyte count decreased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with lymphocyte count decreased abnormality, by CTCAE maximum grade ^[19] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 9 | 4 | 0 | 0 |
| Grade 1 | 5 | 2 | 3 | 2 |
| Grade 2 | 1 | 1 | 5 | 2 |
| Grade 3 | 0 | 0 | 1 | 2 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 2 | 1 | 1 | |
| Grade 1 | 3 | 1 | 1 | |
| Grade 2 | 5 | 1 | 2 | |
| Grade 3 | 1 | 1 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with lymphocyte count increased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with lymphocyte count increased abnormality, by CTCAE maximum grade ^[20] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 15 | 7 | 9 | 6 |
| Grade 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 11 | 4 | 4 | |
| Grade 1 | 0 | 0 | 0 | |
| Grade 2 | 0 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with neutrophil count decreased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with neutrophil count decreased abnormality, by CTCAE maximum grade ^[21] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 12 | 6 | 7 | 5 |
| Grade 1 | 3 | 0 | 1 | 1 |
| Grade 2 | 0 | 1 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 10 | 3 | 0 | |
| Grade 1 | 1 | 0 | 0 | |
| Grade 2 | 0 | 0 | 1 | |
| Grade 3 | 0 | 1 | 0 | |
| Grade 4 | 0 | 0 | 3 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with platelet count decreased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with platelet count decreased abnormality, by CTCAE maximum grade ^[22] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 14 | 6 | 8 | 5 |
| Grade 1 | 1 | 1 | 1 | 1 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 5 | 2 | 2 | |
| Grade 1 | 5 | 2 | 2 | |
| Grade 2 | 1 | 0 | 0 | |
| Grade 3 | 0 | 0 | 0 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with white blood cell decreased abnormality, by CTCAE maximum grade

| | |
|-----------------|--|
| End point title | Number of subjects with white blood cell decreased abnormality, by CTCAE maximum grade ^[23] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Grade 0 | 13 | 7 | 6 | 3 |
| Grade 1 | 2 | 0 | 2 | 2 |
| Grade 2 | 0 | 0 | 1 | 1 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Grade 0 | 7 | 2 | 0 | |
| Grade 1 | 4 | 1 | 1 | |
| Grade 2 | 0 | 1 | 0 | |
| Grade 3 | 0 | 0 | 3 | |
| Grade 4 | 0 | 0 | 0 | |
| Grade Unknown | 0 | 0 | 4 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of patients with adverse events (AEs), by CTCAE maximum grade reported

| | |
|-----------------|---|
| End point title | Number of patients with adverse events (AEs), by CTCAE maximum grade reported ^[24] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any AE(s) Grade 1 | 6 | 1 | 0 | 0 |
| Any AE(s) Grade 2 | 6 | 4 | 6 | 0 |
| Any AE(s) Grade 3 | 3 | 0 | 0 | 5 |
| Any AE(s) Grade 4 | 0 | 0 | 2 | 1 |
| Any AE(s) Grade 5 | 0 | 0 | 1 | 0 |
| Any AE(s) | 15 | 5 | 9 | 6 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any AE(s) Grade 1 | 0 | 0 | 0 | |
| Any AE(s) Grade 2 | 4 | 3 | 2 | |
| Any AE(s) Grade 3 | 3 | 0 | 1 | |
| Any AE(s) Grade 4 | 4 | 1 | 4 | |
| Any AE(s) Grade 5 | 0 | 0 | 0 | |
| Any AE(s) | 11 | 4 | 7 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with serious adverse events (SAEs), by CTCAE maximum grade reported

| | |
|-----------------|--|
| End point title | Number of subjects with serious adverse events (SAEs), by CTCAE maximum grade reported ^[25] |
|-----------------|--|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any SAE(s) Grade 1 | 0 | 0 | 0 | 0 |
| Any SAE(s) Grade 2 | 1 | 0 | 1 | 0 |
| Any SAE(s) Grade 3 | 2 | 0 | 0 | 1 |
| Any SAE(s) Grade 4 | 0 | 0 | 2 | 1 |
| Any SAE(s) Grade 5 | 0 | 0 | 1 | 0 |
| Any SAE(s) | 3 | 0 | 4 | 2 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any SAE(s) Grade 1 | 0 | 0 | 0 | |
| Any SAE(s) Grade 2 | 0 | 0 | 0 | |
| Any SAE(s) Grade 3 | 1 | 0 | 1 | |
| Any SAE(s) Grade 4 | 4 | 1 | 4 | |
| Any SAE(s) Grade 5 | 0 | 0 | 0 | |
| Any SAE(s) | 5 | 1 | 5 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with adverse events (AEs) assessed by the investigators as causally related to WT1 ASCI treatment, by CTCAE maximum grade reported

| | |
|-----------------|---|
| End point title | Number of subjects with adverse events (AEs) assessed by the investigators as causally related to WT1 ASCI treatment, by CTCAE maximum grade reported ^[26] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any related AE(s) Grade 1 | 7 | 2 | 0 | 0 |
| Any related AE(s) Grade 2 | 4 | 0 | 3 | 0 |
| Any related AE(s) Grade 3 | 1 | 0 | 0 | 0 |
| Any related AE(s) Grade 4 | 0 | 0 | 0 | 0 |
| Any related AE(s) Grade 5 | 0 | 0 | 0 | 0 |
| Any related AE(s) | 12 | 2 | 3 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any related AE(s) Grade 1 | 5 | 0 | 2 | |
| Any related AE(s) Grade 2 | 1 | 1 | 4 | |
| Any related AE(s) Grade 3 | 1 | 0 | 0 | |
| Any related AE(s) Grade 4 | 0 | 0 | 0 | |
| Any related AE(s) Grade 5 | 0 | 0 | 0 | |
| Any related AE(s) | 7 | 1 | 6 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with serious adverse events (SAEs), assessed by the investigators as causally related to WT1 ASCI treatment, by CTCAE maximum grade reported

| | |
|-----------------|---|
| End point title | Number of subjects with serious adverse events (SAEs), assessed by the investigators as causally related to WT1 ASCI treatment, by CTCAE maximum grade reported ^[27] |
|-----------------|---|

End point description:

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period and up to 30 days post last administration

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 15 | 7 | 9 | 6 |
| Units: Subjects | | | | |
| Any related SAE(s) Grade 1 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 2 | 1 | 0 | 0 | 0 |
| Any related SAE(s) Grade 3 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 4 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 5 | 0 | 0 | 0 | 0 |
| Any related SAE(s) | 1 | 0 | 0 | 0 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 8 | |
| Units: Subjects | | | | |
| Any related SAE(s) Grade 1 | 0 | 0 | 0 | |
| Any related SAE(s) Grade 2 | 0 | 0 | 0 | |
| Any related SAE(s) Grade 3 | 1 | 0 | 0 | |
| Any related SAE(s) Grade 4 | 0 | 0 | 0 | |
| Any related SAE(s) Grade 5 | 0 | 0 | 0 | |
| Any related SAE(s) | 1 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of subjects with breast cancer pathological response

| | |
|-----------------|---|
| End point title | Number of subjects with breast cancer pathological response ^[28] |
|-----------------|---|

End point description:

The pathological response in lymph nodes was evaluated by presence or absence of tumor cells by histopathological examination. Partial responses mark the disappearance of tumor cells, with only small clusters or dispersed cells remaining (more than 90% loss) while complete response indicate no identifiable malignant cells. However, ductal carcinoma in situ may be present.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the treatment period, up to Week 26/32

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group | Cohort B-Placebo Group |
|-----------------------------|--------------------|------------------------|--------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 13 | 6 | 9 | 6 |
| Units: Subjects | | | | |
| Partial response | 4 | 3 | 5 | 3 |
| Complete response | 0 | 0 | 0 | 2 |

| End point values | Cohort C-WT1 Group | Cohort C-Placebo Group | Cohort D-WT1-D14 Group | |
|-----------------------------|--------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 4 | 4 | |
| Units: Subjects | | | | |
| Partial response | 3 | 1 | 3 | |
| Complete response | 6 | 3 | 1 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs were reported during the treatment period and up to 30 days post last administration. SAEs during the entire study period (Week 0 to Week 26/32).

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 18.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | Cohort A-WT1 Group |
|-----------------------|--------------------|

Reporting group description:

This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of WT1 ASCI according to treatment schedule.

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort A-Placebo Group |
|-----------------------|------------------------|

Reporting group description:

This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of placebo, according to the treatment schedule.

| | |
|-----------------------|--------------------|
| Reporting group title | Cohort B-WT1 Group |
|-----------------------|--------------------|

Reporting group description:

This group included breast cancer patients who received WT1-ASCI, Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel, according to the treatment schedule.

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort B-Placebo Group |
|-----------------------|------------------------|

Reporting group description:

This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|-----------------------|--------------------|
| Reporting group title | Cohort C-WT1 Group |
|-----------------------|--------------------|

Reporting group description:

This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1-ASCI, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort C-Placebo Group |
|-----------------------|------------------------|

Reporting group description:

This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| | |
|-----------------------|------------------------|
| Reporting group title | Cohort D-WT1-D14 Group |
|-----------------------|------------------------|

Reporting group description:

This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1-ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

| Serious adverse events | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group |
|---|--------------------|------------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 0 / 7 (0.00%) | 4 / 9 (44.44%) |
| number of deaths (all causes) | 0 | 0 | 1 |

| | | | |
|---|----------------|---------------|----------------|
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Renal cancer | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Death | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Ear and labyrinth disorders | | | |
| Vestibular disorder | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|---------------|----------------|
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |

| | | | |
|---|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 1 / 9 (11.11%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Cohort B-Placebo Group | Cohort C-WT1 Group | Cohort C-Placebo Group |
|---|------------------------|--------------------|------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 5 / 11 (45.45%) | 1 / 4 (25.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 4 / 11 (36.36%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 1 / 11 (9.09%) | 1 / 4 (25.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 11 (9.09%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Death | | | |

| | | | |
|---|---------------|-----------------|---------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 11 (18.18%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 11 (9.09%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 11 (9.09%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|----------------|---------------|
| Musculoskeletal and connective tissue disorders | | | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 11 (9.09%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------------|--|--|
| Serious adverse events | Cohort D-WT1-D14 Group | | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 8 (62.50%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Neutropenia | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Febrile neutropenia | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 2 / 8 (25.00%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Death | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ear and labyrinth disorders | | | |
| Vestibular disorder | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nausea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|----------------|--|--|
| Vomiting | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Myalgia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Cohort A-WT1 Group | Cohort A-Placebo Group | Cohort B-WT1 Group |
|---|--------------------|------------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 15 / 15 (100.00%) | 5 / 7 (71.43%) | 9 / 9 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| Bowen's disease subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 9 (0.00%) 0 |
| Vascular disorders | | | |
| Hot flush subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| General disorders and administration site conditions | | | |
| Fatigue alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 3 / 15 (20.00%) 3 | 1 / 7 (14.29%) 1 | 8 / 9 (88.89%) 8 |
| Injection site pain subjects affected / exposed occurrences (all) | 4 / 15 (26.67%) 4 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Injection site erythema subjects affected / exposed occurrences (all) | 5 / 15 (33.33%) 5 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Mucosal inflammation subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 3 / 9 (33.33%) 3 |
| Injection site reaction subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Injection site swelling subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Oedema peripheral subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 3 / 9 (33.33%) 3 |
| Chills subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |

| | | | |
|---|----------------------|---------------------|---------------------|
| Injection site discomfort subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Injection site haematoma subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 9 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 3 / 9 (33.33%) 3 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Investigations Weight decreased subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 9 (0.00%) 0 |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 5 / 15 (33.33%) 5 | 1 / 7 (14.29%) 1 | 1 / 9 (11.11%) 1 |
| Peripheral sensory neuropathy | | | |

| | | | |
|---|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 7 (14.29%) 1 | 2 / 9 (22.22%) 2 |
| Dysgeusia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Neutropenia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Anaemia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Febrile neutropenia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Nausea subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 6 / 9 (66.67%) 6 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 3 / 9 (33.33%) 3 |
| Stomatitis | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 0 | 2 |
| Constipation | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 2 / 9 (22.22%) |
| occurrences (all) | 0 | 0 | 2 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 3 / 9 (33.33%) |
| occurrences (all) | 0 | 0 | 3 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 4 / 9 (44.44%) |
| occurrences (all) | 0 | 0 | 4 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 7 (14.29%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 9 / 9 (100.00%) |
| occurrences (all) | 0 | 0 | 9 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 7 (0.00%) | 0 / 9 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | 2 / 7 (28.57%) | 2 / 9 (22.22%) |
| occurrences (all) | 3 | 2 | 2 |
| Myalgia | | | |

| | | | |
|--|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 4 / 15 (26.67%) 4 | 0 / 7 (0.00%) 0 | 4 / 9 (44.44%) 4 |
| Bone pain subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 3 / 9 (33.33%) 3 |
| Back pain subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Infections and infestations | | | |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Gingivitis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 2 / 9 (22.22%) 2 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Pharyngitis subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |
| Influenza subjects affected / exposed occurrences (all) | 0 / 15 (0.00%) 0 | 1 / 7 (14.29%) 1 | 0 / 9 (0.00%) 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 2 / 15 (13.33%) 2 | 0 / 7 (0.00%) 0 | 0 / 9 (0.00%) 0 |

| Non-serious adverse events | Cohort B-Placebo Group | Cohort C-WT1 Group | Cohort C-Placebo Group |
|--|---------------------------|--------------------|---------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 6 / 6 (100.00%) | 11 / 11 (100.00%) | 4 / 4 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---|---------------------|----------------------|----------------------|
| Bowen's disease subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Vascular disorders | | | |
| Hot flush subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Flushing subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Fatigue alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 4 / 6 (66.67%) 4 | 7 / 11 (63.64%) 7 | 4 / 4 (100.00%) 4 |
| Injection site pain subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 4 / 11 (36.36%) 4 | 0 / 4 (0.00%) 0 |
| Injection site erythema subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 11 (27.27%) 3 | 0 / 4 (0.00%) 0 |
| Mucosal inflammation subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 11 (27.27%) 3 | 2 / 4 (50.00%) 2 |
| Injection site reaction subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Injection site swelling subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Oedema peripheral subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Chills subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |

| | | | |
|---|---------------------|----------------------|--------------------|
| Injection site discomfort subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Injection site haematoma subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Investigations Weight decreased subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 11 (27.27%) 3 | 0 / 4 (0.00%) 0 |
| Peripheral sensory neuropathy | | | |

| | | | |
|---|---------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 5 / 11 (45.45%) 5 | 2 / 4 (50.00%) 2 |
| Dysgeusia subjects affected / exposed occurrences (all) | 3 / 6 (50.00%) 3 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Neutropenia subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 4 / 11 (36.36%) 4 | 0 / 4 (0.00%) 0 |
| Anaemia subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 4 / 11 (36.36%) 4 | 0 / 4 (0.00%) 0 |
| Leukopenia subjects affected / exposed occurrences (all) | 3 / 6 (50.00%) 3 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Febrile neutropenia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Nausea subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 8 / 11 (72.73%) 8 | 2 / 4 (50.00%) 2 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 11 (27.27%) 3 | 0 / 4 (0.00%) 0 |
| Stomatitis | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 2 / 6 (33.33%) | 2 / 11 (18.18%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 4 / 11 (36.36%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 5 / 6 (83.33%) | 8 / 11 (72.73%) | 3 / 4 (75.00%) |
| occurrences (all) | 5 | 8 | 3 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 11 (18.18%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 11 (18.18%) | 0 / 4 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 11 (0.00%) | 2 / 4 (50.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Renal and urinary disorders | | | |
| Pollakiuria | | | |
| subjects affected / exposed | 2 / 6 (33.33%) | 0 / 11 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 11 (27.27%) | 2 / 4 (50.00%) |
| occurrences (all) | 0 | 3 | 2 |
| Myalgia | | | |

| | | | |
|--|---------------------|----------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Bone pain subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Back pain subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 11 (27.27%) 3 | 0 / 4 (0.00%) 0 |
| Infections and infestations Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Gingivitis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 2 / 6 (33.33%) 2 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Pharyngitis subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 2 / 11 (18.18%) 2 | 0 / 4 (0.00%) 0 |
| Influenza subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |
| Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 11 (0.00%) 0 | 0 / 4 (0.00%) 0 |

| | | | |
|---|---------------------------|--|--|
| Non-serious adverse events | Cohort D-WT1-D14 Group | | |
| Total subjects affected by non-serious adverse events subjects affected / exposed | 7 / 8 (87.50%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|--|---------------------|--|--|
| Bowen's disease subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Vascular disorders Hot flush subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Flushing subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| General disorders and administration site conditions Fatigue alternative assessment type: Systematic subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Injection site pain subjects affected / exposed occurrences (all) | 4 / 8 (50.00%) 4 | | |
| Injection site erythema subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Mucosal inflammation subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Injection site reaction subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Injection site swelling subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Oedema peripheral subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Chills subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |

| | | | |
|---|--|--|--|
| Injection site discomfort subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Injection site haematoma subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0 | | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Investigations Weight decreased subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Injury, poisoning and procedural complications Procedural pain subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | | |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0 | | |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) Peripheral sensory neuropathy | 2 / 8 (25.00%) 2 | | |

| | | | |
|---|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Dysgeusia subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Neuropathy peripheral subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Blood and lymphatic system disorders | | | |
| Neutropenia subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 3 | | |
| Anaemia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Leukopenia subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Febrile neutropenia subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | | |
| Gastrointestinal disorders | | | |
| Nausea subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 3 | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 2 | | |
| Stomatitis | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 2 / 8 (25.00%) | | |
| occurrences (all) | 2 | | |
| Constipation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vomiting | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | | |
| occurrences (all) | 3 | | |
| Dry skin | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pruritus | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myalgia | | | |

| | | | |
|------------------------------------|----------------|--|--|
| subjects affected / exposed | 2 / 8 (25.00%) | | |
| occurrences (all) | 2 | | |
| Bone pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gingivitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Influenza | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | | |
| occurrences (all) | 0 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|--|
| 13 January 2011 | <ol style="list-style-type: none">1. Change in placebo from a lyophilized sucrose formulation reconstituted with a 1/500 dilution of SB62 oil-in-water emulsion to a lyophilized sucrose/mannitol formulation reconstituted with the same dilution of the SB62 oil-in-water emulsion. This change was implemented due to differences in cake height of the lyophilized sucrose formulation compared to lyophilized WT1-A10 and CpG 7909, which would compromise the double blinding of the study.2. Extension of active follow-up of patients from one to three years. This was requested by the Agence Française de Sécurité Sanitaire des Produits the Santé.3. In the safety Section (Section 9.1.3), the list of autoimmune diseases to be reported has been replaced by a list of potential immune-mediated diseases (pIMDs). pIMDs include autoimmune diseases and other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Moreover, it is specified that all pIMDs will be recorded in the eCRF and reported to GSK Biologicals within 24 hours using the Serious Adverse Event (SAE) screen, regardless of whether the pIMDs are AEs or SAEs. This ensures expedited reporting of all pIMDs. In addition, SAEs related to study treatment are introduced as a separate category of adverse events, to be recorded from receipt of the first study product until the end of follow -up. Contact information for an emergency unblinding request has also been updated.4. In the sections describing the molecular and immunological read-outs and the translational research, the distinction between the use of fresh tumor samples or Formalin-Fixed, Paraffin Embedded (FFPE) samples for specific tests has been removed. This allows the use of any of these two types of samples in case updated technologies would be employed for specific analyses. Moreover, it is specified that if appropriate, plasma derived from Peripheral Blood Mononuclear Cell (PBMC) purification may be used as backup material for serum in some tests. |
| 26 August 2011 | <ul style="list-style-type: none">• In case of cardiac assessment during treatment, it has been specified that for patients on 18-week regimens, this assessment should be done between Visit 3 and Visit 4, such that results are available at Visit 4.• Instructions for the processing of tissue samples collected from the resected tumor or tumor bed have been adapted.• Based on feedback from investigators during the investigators' meeting the following additional changes were done:• The extension of a cohort into the Phase II part of the study depends on the outcome of an intermediate assessment of the immunogenicity of the investigational treatment. The serum sample to be used for this evaluation has been changed from a Post-dose 3 sample to a Post-dose 4 sample to ascertain that sufficient time is allowed for an immune response to develop.• The strict timings for screening tests/examinations are made less stringent. All assessments required for screening, except pregnancy testing can be performed within four weeks prior to randomization of the patient.• Exclusion criterion no 13 (Section 4.4) has been rephrased to make clear that only patients receiving therapeutic anticoagulation are excluded from the study.• In the context of postponement of study treatment in an individual patient, the parameters for blood/bone marrow disorders have been adapted for Cohort B and C, such as to avoid frequent postponement of study treatment administration due to side effects of standard treatment.• The tumor imaging at Visit 4 as well as the post-treatment systemic imaging during the presurgery period have been changed from being mandatory to being optional (according to the investigator's discretion). The description of tumor imaging has been clarified. |

| | |
|---------------|--|
| 08 April 2013 | <ul style="list-style-type: none"> The analysis of the immunogenicity results of the cohort B (unblinded data) evaluating the concurrent administration of the WT1-A10 + AS15 ASCI on day 1 of each cycle of neoadjuvant chemotherapy and during the corticosteroids treatment showed that the above criteria was not fulfilled. Therefore enrolment into the Phase II segment of cohort B has been stopped. But preliminary data has suggested the induction of an anti-WT1 humoral response by the WT1-A10 + AS01B ASCI in absence of concurrent administration of chemotherapy and corticosteroids in two other clinical studies in acute myeloid leukemia. So, the administration of the WT1-A10 + AS15 ASCI will also be evaluated on day 14 of each cycle of neoadjuvant chemotherapy in a new cohort of patients, in order to gain a better understanding of the role of the chemotherapy and corticosteroids on the immune response induced by the WT1-A10 + AS15 ASCI. The patients in this new cohort, the cohort D, will receive the WT1-A10 + AS15 ASCI at day 14 (D14) of each cycle of the standard neoadjuvant chemotherapy in an open label, non-randomised design. In the absence of a safety signal and if the WT1-A10 + AS15 ASCI induces an adequate immune response according the same rules defined per protocol (see section 3.1.3.1), an additional group of patients with the same eligibility criteria may be recruited in a double blind, randomised phase II segment of the study (Cohort E). These patients will be randomised to receive either WT1-A10 + AS15 ASCI or placebo on D14 of each cycle of neoadjuvant chemotherapy. The patient population eligible for cohorts D and E is presenting a hormone receptor-positive and HER2 non-overexpressing breast cancer. Also, the assessment of the anti-CpG7909 humoral response and the anti-WT1 T-cell immune response was moved to translational research section as these assessments are not part of the endpoints of the study and will have no direct impact on the study design, i.e. decision making process. |
|---------------|--|

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|--------------|--|--------------|
| 18 July 2014 | The study was terminated, based on scientific and medical relevance, due to negative Phase III studies which assessed another study product from same technology platform. | - |

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The Phase II segment was not completed with only 3 patients enrolled in Cohort A. Consequently, analysis for DFS and OS outcomes was cancelled and the collected clinical activity results are to be considered with caution and uninterpretable.

Notes: